


Molecular testing outperforms traditional methods for gastrointestinal infections



The healthcare burden of gastrointestinal infections and limitations of traditional methods



Why integrate molecular techniques in microbiology workflow?

Molecular techniques speed up accurate diagnoses



- Significantly **faster** with **higher sensitivity** than existing culture-based methods²
- Early detection or early identification of diseases requiring antibiotics may save lives and **prevent unnecessary use of antibiotics**⁷
- Early detection or exclusion of pathogens aid in **faster treatment decisions** and may reduce hospital length of stay⁷
- Accurate and rapid pathogen identification are crucial to **minimise outbreak risk**⁸
- Initial testing with one consolidated technique** for the most common bacteria, parasites, and viruses



Why is speed and accurate diagnoses important for gastrointestinal infections?



Rapid identification of Shiga toxin-producing *E. coli* (STEC) is critical for patients as infections can cause severe complications of haemolytic-uremic syndrome, kidney failure, and neurological issues⁹

Wrongly prescribing **antibiotics** may **increase** the production of the **Shiga toxin**⁹

The International Society for Infectious Diseases (ISID) recommends that a patient with infectious diarrhoea is placed in a private room¹⁰

Campylobacter diagnosis using culture methods risks false-negative results¹¹

Cultures for *Campylobacter* produced **false results at a rate of 30%**¹¹

Helps prevent inappropriate antibiotic use that might lead to antibiotic-resistant *Campylobacter* strains¹¹

Microscopic examination fails to differentiate *Entamoeba histolytica* from the non-pathogenic *Entamoeba dispar*¹²

Molecular methods can differentiate between pathogenic and non-pathogenic species to avoid missing diagnoses or giving unnecessary treatment¹²



Improve workflow efficiency for timely patient management with the BD MAX™ System



>90%


- Only **1.5 mins** of hands-on time per sample¹³
- 24 patient results** in **2 to 3 hours**, on average^{13,17}
- Same day results**, with 4 runs in one 8-hour shift¹³
- Coverage for **>90%** of pathogens causing infectious diarrhoea¹⁴

Key advantages of the BD MAX™ System vs. traditional methods and other molecular platforms?



Easy to use BD MAX™ System requires less hands-on time ^{15,16}	Fully automated and integrated system for an easy and effective set up and run process ¹⁷	Reduced risk of contamination and human error ^{15,17}
<ul style="list-style-type: none"> No need for extensive daily manual machine set up No need to manually prepare reagents prior to processing (No mixing, no manual preparation of proteinase K, no freeze thaw cycles, no centrifuge) No need for 4°C or -20°C storage. Room temperature storage close to the instrument Does not require skilled technicians¹³. Limited training is required to use the machine efficiently 	<ul style="list-style-type: none"> Allows the user to walk away or run samples overnight Interleave run allows for 96 results in an 8-hour shift Flexibility of 1 to 24 specimens with 2 independent racks Multiple assays being run compatible for an optimised and flexible testing* Off-hour testing is facilitated by ease of use and reduced manual requirements 	<ul style="list-style-type: none"> Low risk of cross-contamination: All reagents and required tips are included in the assay kits of the BD MAX™ System. Extraction and PCR reagents are single-use-only so no need to recap or store them Limited human intervention: BD MAX™ takes care of all processing steps Bi-directional Laboratory Information System communication Automatic interpretation of the results with user friendly software All consumables are barcoded for full chain of custody

Run workflow comparison†



* BD assays are run & rack compatible – Only MDR-TB is not run and rack compatible / Vaginal Panel, GBS and open system assays are only run compatible.
 † Timing for semi-automated platforms is indicative (platform & batch-size dependent)
 ‡ May require cartridge change in case of interleave run

References

- Mirabelli C, Santos-Ferreira N, Gilliland MG, et al. Human Norovirus Efficiently Replicates in Differentiated 3D-Human Intestinal Enteroids. *J Virol*. 2022;96(22):e0085522. doi:10.1128/jvi.00855-22
- Amjad M. An Overview of the Molecular Methods in the Diagnosis of Gastrointestinal Infectious Diseases. *Int J Microbiol*. 2020;2020:8135724. doi:10.1155/2020/8135724
- Lee JY, Cho SY, Hwang HSH, et al. Diagnostic yield of stool culture and predictive factors for positive culture in patients with diarrheal illness. *Medicine (Baltimore)*. 2017;96(30):e7641. doi:10.1097/MD.00000000000007641
- Kaplan J, Ferraro MJB, Fineberg H, Rosenberg M. Value of stool cultures. *The Lancet*. 1980;316(8191):413-416.
- Chau ML, Hartantyo SHP, Yap M, et al. Diarrheagenic pathogens in adults attending a hospital in Singapore. *BMC Infect Dis*. 2016;16(1). doi:10.1186/s12879-016-1354-0
- Rohner P, Pittet D, Pepey B, Nije-Kinge T, Auckenthaler R. Etiological agents of infectious diarrhea: implications for requests for microbial culture. *J Clin Microbiol*. 1997;35(6):1427-1432. Vol 35; 1997.
- NICE. *BD MAX Enteric Bacterial Panel for Identifying Pathogens in Contagious Gastroenteritis Medtech Innovation Briefing*; 2015. www.nice.org.uk/guidance/mib32
- Priyanka B, Patil RK, Dwarkanath S. A review on detection methods used for foodborne pathogens. *Indian J Med Res*. 2016;144(3):327-338. doi:10.4103/0971-5916.198677
- Mühlen S, Dersch P. Treatment Strategies for Infections With Shiga Toxin-Producing *Escherichia coli*. *Front Cell Infect Microbiol*. 2020;10. doi:10.3389/fcimb.2020.00169
- International Society for Infectious Diseases. Guide to Infection Control in the Healthcare Setting - Diarrhea. <https://isid.org/guide/hospital/diarrhea/>. Access June 14, 2023.
- Buss JE, Cresse M, Doyle S, Buchan BW, Craft DW, Young S. *Campylobacter* culture fails to correctly detect *Campylobacter* in 30% of positive patient stool specimens compared to non-cultural methods. *Eur J Clin Microbiol Infect Dis*. 2019;38(6):1087-1093. doi:10.1007/s10096-019-03499-x
- Mohammed F, Taha A, Salama M. Differentiation of *Entamoeba histolytica* from *Entamoeba dispar* by nested multiplex polymerase chain reaction. *Parasitologists United Journal*. 2017;10(1-2):23-29. doi:10.21608/puj.2017.4732
- Felder RA, Jackson KD, Walter AM. Process Evaluation of an Open Architecture Real-Time Molecular Laboratory Platform. *J Lab Autom*. 2014;19(5):468-473. doi:10.1177/2211068214533195
- Sidoti F, Rittà M, Costa C, Cavallo R. Diagnosis of viral gastroenteritis: limits and potential of currently available procedures. *J Infect Dev Ctries*. 2015;9(06):551-561. doi:10.3855/jidc.7051
- Becton Dickinson and Company. BD MAX System User's Manual International Windows Version. *Spark, MD*. 2022;Rev.12.
- Becton Dickinson and Company. BD MAX™ Enteric Bacterial Panel [IFU 442963].
- BD Internal Data.

